Medicus Licenses Pfizer’s CD228V ADC

Companies: Medicus Pharma / Pfizer · Asset: CD228V (PF-08046031, Antibody-Drug Conjugate) · Deal Terms: $12M Upfront + $15M Year-1 + >$1B Milestones · Territory: Worldwide · Date: September 2, 2026 Summary Medicus Pharma licensed exclusive worldwide rights to Pfizer’s early clinical-stage CD228-targeted antibody-drug conjugate, CD228V/PF-08046031,…

🔒

Continue reading this signal

Create a free InSilens account to unlock full articles, analysis, and deal context.

Create Free Account
Tags
Share this article :

Leave a Reply

Your email address will not be published. Required fields are marked *

Saturday Rounds

Genentech / Astex | Breast Cancer Discovery Collaboration Amid gRED Restructuring
Sobi Licenses Lacutamab in $580 Million Deal
Neomorph – $100M Molecular Glue Financing
Dyne Seeks $300 Million After BLA Acceptance